Mode DX, a life sciences spin-out of the University of Glasgow, secures series B from prominent UK investors.

Allergy drug development firm Circassia floats on the London Stock Exchange in the biggest UK biotech initial public offering in years.

Liverpool John Moores University commercialises lung biosimulator with fresh spin-out Pulmorphix.

Two teams from the University of Cambridge are among ten winners in a competition to bring breast cancer treatments to market.

The deal also marks the first exit for the $35m Partners Innovation Fund, a corporate and academic research venturing unit of Partners HealthCare System, a US-based hospital and physicians group covering Brigham and Women's Hospital, Massachusetts General Hospital, and McLean Hospital.